TheraRadar
Clinical-Stage Companies / Medipost

Medipost

Pre-Approval PRO BETA

Also known as: Medipost, Inc., Medipost Co Ltd.

16
Total Trials
3
Phase 3
10
Phase 2
3
Recruiting
154
Score

Pipeline by Phase

Phase 3
3
Phase 2
10
Phase 1
8

Therapeutic Focus

Bronchopulmonary Dysplasia Knee Osteoarthritis Alzheimer's Disease Knee Cartilage Defects Degeneration Articular Cartilage Knee

Clinical Trials (16)

NCT07339111 Phase 3 RECRUITING

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

Started: 3/11/2026

NCT01041001 Phase 3 COMPLETED

Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury

Started: 2/1/2009

NCT01626677 Phase 3 COMPLETED

Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect

Started: 6/1/2012

NCT06798727 Phase 2 ACTIVE NOT RECRUITING

Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control

Started: 3/20/2023

NCT04003857 Phase 2 ACTIVE NOT RECRUITING

Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

Started: 7/5/2019

NCT05182034 Phase 2 COMPLETED

Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis

Started: 2/24/2022

NCT03392467 Phase 2 COMPLETED

PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants

Started: 8/13/2018

NCT01828957 Phase 2 COMPLETED

Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants

Started: 4/1/2013

NCT01733186 Phase 1 COMPLETED

Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects

Started: 1/7/2013

NCT02381366 Phase 1 COMPLETED

Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study

Started: 3/1/2015

NCT03172117 Phase 1 COMPLETED

Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.

Started: 5/19/2017

NCT04037345 Phase 1 COMPLETED

Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis

Started: 10/7/2019

NCT02054208 Phase 1 COMPLETED

Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease

Started: 3/1/2014

NCT01297205 Phase 1 COMPLETED

Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia

Started: 12/1/2010

NCT00823316 Phase 1 COMPLETED

Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation

Started: 8/1/2008

NCT01297218 Phase 1 COMPLETED

The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease

Started: 2/1/2011

Drug Candidates

CARTISTEM® + Debridement CARTISTEM® Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells SMUP-IA-01(low-dose) SMUP-IA-01(mid-dose) High Hyal Plus PNEUMOSTEM® normal saline SMUP-IA-01(low dose) SMUP-IA-01(mid dose)
Activity Status: Active
Last Trial Started: 3/11/2026
Last Trial Ended: 10/18/2024
Trials (12 months): 1
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.